OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology-Neuroimmunology & Neuroinflammation is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	157
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	91
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	89
Antibody-Negative Autoimmune Encephalitis	80
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	79
MOG IgG3-Subclass Antibodies in MOG-Associated Disease	69
Elevated ITGAX/CD11c in CSF-Derived Extracellular Vesicles Reflects Disability Progression in Multiple Sclerosis	68
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	68
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	66
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	65
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	62
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	62
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	61
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	60
Treatment With Erythropoietin for Patients With Optic Neuritis	59
Peripheral HLA-DR ^hi CD141 ⁺ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis	59
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	59
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	58
Acute Paresthesia and Ataxia in a Child	56
Plasma N -Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD, and MOGAD	53
Should We Measure CSF Complement Levels in Patients With MOGAD?	52
Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis	51
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	49
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	49
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	49

Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	47
Toward Precision Phenotyping of Multiple Sclerosis	46
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	46
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	45
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	45
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	44
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis	44
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	43
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	42
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	40
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	40
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	36